Quoin pharmaceuticals files u.s. patent application for novel topical formulations to treat netherton syndrome and other skin diseases

Ashburn, va., march 25, 2025 (globe newswire) -- quoin pharmaceuticals ltd. (nasdaq: qnrx) (the “company” or “quoin”), a late-stage clinical, specialty pharmaceutical company focused on the development and commercialization of therapeutic products that treat rare and orphan diseases, today announced it has filed a u.s. patent application for novel topical formulations to treat a number of skin diseases, including netherton syndrome (ns). quoin's lead product, qrx003, is currently being tested in four netherton syndrome clinical trials. three of these trials are being conducted under quoin's open investigational new drug (ind) application with the us food and drug administration (fda). qrx003 is also currently being tested in a pediatric ns patient at the children's hospital in dublin, ireland and the company intends to expand this study to include additional children with ns in spain, the united kingdom and potentially other countries. the company has recently reported positive initial clinical data from the two open label studies for which data is available. this patent application also includes peeling skin syndrome for which quoin has an ongoing investigator clinical study in a pediatric patient in new zealand. there are currently no fda approved treatments for either netherton syndrome or peeling skin syndrome.
QNRX Ratings Summary
QNRX Quant Ranking